Baxter International Inc. (NYSE:BAX) named Ludwig Hantson president of its international operations, effective May 3.
The Deerfield, Ill.-based medical products conglomerate said expanding its global footprint is a “key growth driver” for the company.
Hantson’s pedigree is stamped by years in the pharmaceutical industry. He was CEO of Novartis Pharmaceuticals Corp.’s (NYSE:NVS) Pharma North America division, having joined Novartis in 2001. Before that Hantson spent 13 years at Janssen Pharmaceutica in marketing and clinical R&D roles, according to a press release.
Baxter reported fourth-quarter sales of $3.47 billion, up 10.8 percent compared with $3.13 billion during the same period in 2008. Quarterly net income ticked up half a percent to $572 million, or 94 cents per diluted share, compared with $569 million or 91 cents per diluted share during Q4 2008. The results included a $56 million after-tax hit (9 cents per diluted share) from its move to streamline operations and reflected a 15 percent spike in international sales, after the effects of foreign exchange rates were factored in.
For the full year, Baxter logged sales of $12.56 billion, up 1.7 percent compared with $12.35 billion during 2008. Net income rose to $2.21 billion ($3.59 per diluted share) in 2009, a 9.5 percent increase over $2.01 billion ($3.16 per diluted share) during the prior year. International sales, excluding the impact of foreign currencies, rose 7 percent for the full year.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.